ANI Pharmaceuticals (NASDAQ:ANIP) Earns Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of ANI Pharmaceuticals (NASDAQ:ANIP) in a research note issued to investors on Monday morning,Benzinga reports. The firm currently has a $94.00 target price on the specialty pharmaceutical company’s stock.

A number of other equities analysts have also recently issued reports on the stock. StockNews.com cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Truist Financial raised their price objective on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a report on Tuesday, October 22nd. Raymond James upped their target price on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a report on Wednesday, September 18th. Finally, Piper Sandler started coverage on ANI Pharmaceuticals in a research note on Friday, October 11th. They set an “overweight” rating and a $68.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $77.33.

ANI Pharmaceuticals Trading Down 1.2 %

ANIP opened at $61.00 on Monday. The company has a quick ratio of 3.07, a current ratio of 3.97 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $1.28 billion, a price-to-earnings ratio of -112.25 and a beta of 0.71. The company has a 50-day simple moving average of $58.61 and a 200 day simple moving average of $61.47. ANI Pharmaceuticals has a twelve month low of $48.20 and a twelve month high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, topping analysts’ consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The company had revenue of $148.30 million during the quarter, compared to analysts’ expectations of $144.37 million. During the same quarter in the previous year, the firm earned $1.05 EPS. ANI Pharmaceuticals’s revenue was up 12.5% on a year-over-year basis. Analysts predict that ANI Pharmaceuticals will post 3.5 EPS for the current fiscal year.

Institutional Trading of ANI Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Millennium Management LLC boosted its position in shares of ANI Pharmaceuticals by 1,005.8% during the 2nd quarter. Millennium Management LLC now owns 230,079 shares of the specialty pharmaceutical company’s stock valued at $14,651,000 after purchasing an additional 209,272 shares in the last quarter. Mizuho Markets Americas LLC acquired a new position in ANI Pharmaceuticals in the third quarter valued at approximately $11,670,000. Assenagon Asset Management S.A. boosted its holdings in shares of ANI Pharmaceuticals by 149.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 186,179 shares of the specialty pharmaceutical company’s stock worth $11,107,000 after buying an additional 111,613 shares in the last quarter. F M Investments LLC acquired a new stake in shares of ANI Pharmaceuticals during the 3rd quarter worth approximately $3,686,000. Finally, American Century Companies Inc. increased its stake in shares of ANI Pharmaceuticals by 99.2% in the 2nd quarter. American Century Companies Inc. now owns 99,831 shares of the specialty pharmaceutical company’s stock valued at $6,357,000 after acquiring an additional 49,717 shares in the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.